Pin-Fei Wei

Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma

J. Shih, Chih-Hsin Yang, Pan‐Chyr Yang, 2010, Medical oncology.

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma

Yih-Leong Chang, J. Shih, Chen‐Tu Wu, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical Outcomes in Non–Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR

J. Shih, Pan‐Chyr Yang, J. Yang, 2012, Clinical Cancer Research.

First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.

J. Shih, Yeun-Chung Chang, Y. Chiu, 2008, American journal of respiratory and critical care medicine.

Structural and functional analysis of lorlatinib analogs reveals roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer

T. R. Johnson, M. Mino‐Kenudson, B. Yeap, 2021, bioRxiv.

Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with EGFR-mutated non-small cell lung cancer treated with afatinib

Chia-Ling Wu, Sheng-Kai Liang, Pin-Fei Wei, 2024, ERJ Open Research.